Non-alcoholic fatty liver disease (NAFLD) includes a range of hepatic manifestations,
starting with liver steatosis and potentially evolving towards non-alcoholic steatohepatitis …

Autophagic pathways cross with lipid homeostasis and thus provide energy and essential
building blocks that are indispensable for liver functions. Energy deficiencies are …

Type 2 diabetes mellitus (DM2) is associated closely with non-alcoholic fatty liver disease
(NAFLD) by affecting lipid metabolism, which may lead to non-alcoholic steatohepatitis …

Nonalcoholic fatty liver disease (NAFLD) constitutes a major health concern with the
increasing incidence of obesity and diabetes in many Western countries, reaching a …

Nonalcoholic steatohepatitis (NASH) arises from a variable interplay between environmental
factors and genetic determinants that cannot be completely replicated in animals …

Animal models are crucial for improving our understanding of human pathogenesis,
enabling researchers to identify therapeutic targets and test novel drugs. In the current …

Hepatocellular carcinoma (HCC) is one of the most fatal and fastest-growing cancers.
Recently, non-alcoholic steatohepatitis (NASH) has been recognized as a major HCC …

Non-alcoholic fatty liver disease (NAFLD) is a chronic liver disorder closely linked to obesity,
hyperlipidemia and type 2 diabetes and is increasingly recognized as a major health …

Non-alcoholic fatty liver disease (NAFLD), including non-alcoholic fatty liver (NAFL) and non-
alcoholic steatohepatitis (NASH), represents the hepatic manifestation of obesity and …

Non-alcoholic fatty liver disease and steatohepatitis are highly associated with obesity and
type 2 diabetes mellitus. Cotadutide, a glucagon-like protein-1 receptor (GLP-1R) and …